We report the case of a patient with diabetes presenting a severe insulin-resistance syndrome due to the production of insulin autoantibodies by a lymphocytic lymphoma. We describe the various mechanisms leading to the production of insulin autoantibodies and insulin receptor autoantibodies and review the therapeutic possibilities.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jcjd.2016.02.007 | DOI Listing |
Neuro Oncol
January 2025
Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
Background: Colorectal cancer (CRC) ranks as the fourth most common cause of brain metastasis (BM), with its incidence on the rise. However, the molecular mechanisms driving the formation of these lesions from CRC remain unclear.
Methods: We analyzed the FoundationOne genomic database, which includes over 35,000 CRC samples from both local and metastatic sites.
Nephrology (Carlton)
February 2025
Internal Medicine Department, Shenzhen Bao'an Authentic Tcm Therapy Hospital, Shenzhen, China.
Aim: Type 2 diabetes mellitus (T2DM) is a metabolic syndrome characterised by absolute or relative insufficiency of insulin secretion. The alkaloids from Rhizoma coptidis have potential hypoglycemic effects. Epiberberine (EPI), a protoberberine alkaloid extracted from Rhizome coptidis, has been found to regulate lipid metabolism.
View Article and Find Full Text PDFJ Cachexia Sarcopenia Muscle
February 2025
Department of International Agricultural Technology, Graduate School of International Agricultural Technology, Seoul National University, Seoul, Republic of Korea.
Background: Muscle diseases are serious challenges to human health. Prokineticin receptor 1 (PROKR1) has emerged as a potential target to improve muscle function through increasing oxidative muscle fibres, but there are no clinically applicable synthetic PROKR1 agonists.
Methods: Drugs with biological properties of prokineticin 2 (PK2) were discovered through connectivity map (CMap) analysis.
Diabetes Obes Metab
January 2025
Division of Nephrology and Hypertension, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Aims: To compare the risk of all-cause death and cardiovascular events in new users of insulin glargine, glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i), particularly in subgroups defined by baseline haemoglobin A1C (HbA1C), body mass index (BMI) and estimated glomerular filtration rate (eGFR).
Materials And Methods: We conducted an active comparator, new user design study in a national cohort of 161 405 veterans with type 2 diabetes (T2D) on metformin and initiated insulin glargine (n = 54 375), GLP-1RA (n = 22 145) or SGLT2i (n = 84 885) between 1 January 2018 and 31 December 2021. Patients were followed until 31 March 2023.
Environ Health Perspect
January 2025
State Key Laboratory of Reproductive Medicine and Offspring Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China.
Background: The widespread use of bisphenol A (BPA) has led to universal exposure among the population, raising concerns about its health effects. Epidemiological studies have linked environmentally relevant levels of BPA exposure to obesity.
Objectives: We aimed to uncover the complex mechanisms by which oral exposure during pregnancy with BPA affects the offspring.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!